Crossmark

[Translated article] Characteristics, clinical benefit, and reimbursement of new authorisations for oncohaematology drugs in Spain between 2017 and 2020

Crossref DOI link: https://doi.org/10.1016/j.farma.2024.07.006

Published Print: 2024-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Martínez-Barros, Hilario

Pousada-Fonseca, Álvaro

Pedreira-Bouzas, Jorge

Clopés-Estela, Ana
License Information

Text and Data Mining valid from 2024-11-01

Text and Data Mining valid from 2024-11-01

Version of Record valid from 2024-07-13
More Information

This article is maintained by: Elsevier

Article Title: [Translated article] Characteristics, clinical benefit, and reimbursement of new authorisations for oncohaematology drugs in Spain between 2017 and 2020

Journal Title: Farmacia Hospitalaria

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.farma.2024.07.006

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.farma.2024.04.022

Content Type: article

Copyright: © 2024 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below